Bryn Mawr Capital Management LLC Acquires 19,923 Shares of Cencora, Inc. (NYSE:COR)

Bryn Mawr Capital Management LLC grew its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 335.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,863 shares of the company's stock after purchasing an additional 19,923 shares during the period. Bryn Mawr Capital Management LLC's holdings in Cencora were worth $5,811,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp raised its position in shares of Cencora by 3.8% in the third quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after purchasing an additional 291,867 shares during the period. Wellington Management Group LLP raised its position in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares during the period. Geode Capital Management LLC raised its position in shares of Cencora by 4.7% in the third quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company's stock valued at $941,183,000 after purchasing an additional 189,054 shares during the period. Pacer Advisors Inc. grew its stake in Cencora by 6.7% during the fourth quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock valued at $495,249,000 after acquiring an additional 138,868 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after acquiring an additional 292,600 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.8 %

NYSE COR traded down $2.06 during trading on Friday, hitting $241.40. The company had a trading volume of 571,294 shares, compared to its average volume of 1,470,849. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company's fifty day moving average is $239.34 and its 200-day moving average is $237.46. The company has a market cap of $46.81 billion, a price-to-earnings ratio of 34.36, a price-to-earnings-growth ratio of 1.32 and a beta of 0.49. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora's payout ratio is 31.29%.

Wall Street Analyst Weigh In

Several brokerages recently commented on COR. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective for the company. UBS Group boosted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $277.90.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.